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Abstract
Background: Chemotherapy (CT) resistance in ovarian cancer (OC) is broad and encompasses diverse
unrelated drugs, suggesting more than one mechanism of resistance. To better understand the molecular
mechanisms controlling the immediate response of OC cells to CT exposure, we have performed gene
expression profiling in spheroid cultures derived from six OC cell lines (OVCAR3, SKOV3, TOV-112, TOV-21,
OV-90 and TOV-155), following treatment with 10,0 μM cisplatin, 2,5 μM paclitaxel or 5,0 μM topotecan for 72
hours.
Results: Exposure of OC spheroids to these CT drugs resulted in differential expression of genes associated with
cell growth and proliferation, cellular assembly and organization, cell death, cell cycle control and cell signaling.
Genes, functionally involved in DNA repair, DNA replication and cell cycle arrest were mostly overexpressed,
while genes implicated in metabolism (especially lipid metabolism), signal transduction, immune and inflammatory
response, transport, transcription regulation and protein biosynthesis, were commonly suppressed following all
treatments. Cisplatin and topotecan treatments triggered similar alterations in gene and pathway expression
patterns, while paclitaxel action was mainly associated with induction of genes and pathways linked to cellular
assembly and organization (including numerous tubulin genes), cell death and protein synthesis. The microarray
data were further confirmed by pathway and network analyses.
Conclusion: Most alterations in gene expression were directly related to mechanisms of the cytotoxics actions
in OC spheroids. However, the induction of genes linked to mechanisms of DNA replication and repair in
cisplatin- and topotecan-treated OC spheroids could be associated with immediate adaptive response to
treatment. Similarly, overexpression of different tubulin genes upon exposure to paclitaxel could represent an
early compensatory effect to this drug action. Finally, multicellular growth conditions that are known to alter gene
expression (including cell adhesion and cytoskeleton organization), could substantially contribute in reducing the
initial effectiveness of CT drugs in OC spheroids. Results described in this study underscore the potential of the
microarray technology for unraveling the complex mechanisms of CT drugs actions in OC spheroids and early
cellular response to treatment.
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Ovarian cancer (OC) is the fourth commonest cause of
cancer related death in women [1]. The majority of
patients present with advanced disease, with an overall
five-year survival rate of approximately 30–40% following
debulking surgery, initial platinum-based CT and further
CT at relapse [1]. Combination CT with paclitaxel and a
platinum compound (carboplatin or cisplatin) is the cur-
rent regimen of choice for the treatment of advanced OC
[2]. A number of clinical issues, however, are unresolved
including drug dosage and schedule, duration of treat-
ment, and route of administration [2]. Thus, although sig-
nificant proportions of women respond to CT, the
majority of responders (approximately 50%–75%) even-
tually relapse at a median of 18 to 28 months [3]. Treat-
ment decisions at this juncture include supplementary CT
with topotecan, hormones, surgery, and experimental
agents [4]. Nonetheless, even with these additional treat-
ments, relapse rates remain high and most women with
advanced OC ultimately will die of their disease [5]. CT
resistance in OC is broad and encompasses diverse unre-
lated drugs, suggesting more than one mechanism of
resistance. A number of other cellular factors have
increased expression and activity in drug-resistant OC cell
lines and/or tumor tissues [reviewed in [6]]. However, for
the majority of these factors, in vivo studies have failed to
assess their clinical importance and to translate them into
recommendations for specific therapies or prognosis in
OC patients [7].
The recent advent of microarray-based profiling technolo-
gies has provided an opportunity to simultaneously exam-
ine the relationship between thousands of genes and
clinical phenotypes. Using this approach, several groups,
including ours, have tried to identify gene expression sig-
natures and/or specific biomarker sets of response to first-
line platinum-based CT in OC following debulking sur-
gery [8-13]. These studies have identified different prog-
nostic and predictor gene sets which can distinguish early
from late relapse or disease progression; however, no sig-
nificant overlap was found between the individual predic-
tor lists. Recently, we used an alternative approach to
evaluate the global gene expression in paired tumor sam-
ples taken prior to and post CT treatment from six patients
with predominantly advanced stage, high-grade OC [14].
We have identified a number of genes that were differen-
tially expressed in post-CT tumor samples, including dif-
ferent factors associated with tumor invasion/progression,
control of cell proliferation, and chemoresistance. How-
ever this approach could not reveal mechanisms of early
response to CT treatment since post-CT OC tumors were
available 3 to 40 months following the last CT treatment
[14].
In this study, we have chosen the versatile multicellular
spheroid model [15] to assess early drug action and
instant response to CT treatment in OC cells. Indeed,
experimental three-dimensional models such as multicel-
lular spheroids may provide a better in vitro approxima-
tion of solid tumors [15], and have been used for study of
multicellular resistance [16,17]. Since the rapid acquisi-
tion of resistance probably represents a physiologic mech-
anism of adaptation at the multicellular level and not a
stable genetic change [18], the spheroid model seems to
be more appropriate to study early occurrence of acquired
drug resistance in solid tumors than monolayer cell cul-
tures [15]. Thus, monolayers do not pose the barrier to
drug penetration or provide many of the microenviron-
mental influences found in solid tumors and 3D cultures
[16]. Experimental data indicating that initial exposure to
drug in vivo may induce low, but yet clinically significant
transient resistance [17-19], also support this hypothesis.
Herein, we applied the DNA microarray technology to
investigate the cellular and molecular mechanisms impli-
cated in immediate drug action and early cellular com-
pensatory response to drugs, commonly used as first- or
second-line treatment of OC, including cisplatin, paclit-
axel and topotecan. We present evidence that initial
defense reactions in OC spheroids are mostly associated
with the induction of DNA repair pathways and the impli-
cation of multicellular/adhesion-dependent or -associ-
ated mechanisms.
Results
Common gene expression signatures of OC spheroids 
following treatment with all drugs used (cisplatin, 
paclitaxel and topotecan)
We employed Agilent Human oligonucleotide microar-
rays, containing ~22,000 genes to identify global gene
expression changes in spheroids propagated from six dif-
ferent OC cell lines (OVCAR-3, SKOV-3, OV-90, TOV-21,
TOV-112, TOV-155), following treatment with three dif-
ferent CT drugs (cisplatin [10 μM], topotecan [5 μM] and
paclitaxel [2.5 μM]) for 72 hours. For each drug, the con-
centration used was empirically estimated as the maximal
drug concentration which does not cause a considerable
cell death (less than 20%) and/or changes in spheroid
morphology during the treatment period (data not
shown). Those concentrations were significantly higher
than the IC50 values determined for each cell line, when
grown as monolayer (Table 1).
First, we compared shared gene expression patterns
between control (non-treated) and all cisplatin-, topote-
can- and paclitaxel-treated spheroids derived from the six
cell lines studied, in search for common markers and/or
molecular mechanisms involved in drug action and
immediate treatment response. A subset of 971 differen-
tially expressed genes was selected from all microarrayPage 2 of 21
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followed by filtering on expression level (≥1.5 fold).
Using these selection criteria, we found 348 genes to be
commonly up-regulated and 623 genes to be down-regu-
lated in the CT drugs-treated spheroids [see Additional file
1]. Table 2 shows a list of selected functionally related
groups of genes that were differentially expressed (≥1.5-
fold) in all treated spheroids. As seen from Table 2, com-
parable numbers of genes with previously shown implica-
tion in mechanisms of apoptosis, cell adhesion, cell cycle
control, and stress (defense) response were both up- and
down-regulated in the treated OC spheroids. Genes, func-
tionally associated with DNA repair, DNA replication and
cell cycle arrest were exclusively overexpressed (Table 2A).
Genes implicated in cell growth and maintenance, tran-
scription regulation, signal transduction and transport
were predominantly down-regulated, while genes linked
to immune and inflammatory response, metabolism
(especially lipid metabolism), protein biosynthesis, pro-
tein modification and RNA processing, were uniquely
suppressed following all treatments (Table 2B).
Pathway and network analyses based on the 971 gene list
were generated through the use of Ingenuity Pathways
Analysis (IPA). The IPA analysis confirmed the major
functionally related groups, found to be commonly up- or
down-regulated in drugs-treated OC spheroids. Thus,
pathways linked to cell growth and proliferation, cellular
assembly and organization, cell death, cell cycle control
and cell signaling were both induced and suppressed;
pathways functionally related to DNA replication, recom-
bination and repair and cellular response to therapeutics
were induced, while pathways associated with control of
gene expression, metabolism, transport, immune and
inflammatory response displayed suppression upon treat-
ments with all drugs (Figure 1A).
A network analysis identified 34 highly significant net-
works with score ≥ 13 [see Additional file 2]. As expected,
the five top-scoring networks were associated with func-
tions linked to cellular growth and proliferation, cell
cycle, cell death, cellular movement and metabolism
(Table 3A). A common network obtained upon merging
the five top-scoring networks (Figure 2) recognized sev-
eral important nodes linked with numerous interaction
partners, including cyclin-dependent kinase inhibitor 1A
(CDKN1A, p21, Cip1), caspase 3 (CASP3), breast cancer 1
(BRCA1), proliferating cell nuclear antigen (PCNA), per-
oxisome proliferative activated receptor alpha (PPARA),
cyclin D1 (CCND1), insulin receptor (INSR), integrin
beta 1 (ITGB1), guanine nucleotide binding protein beta
polypeptide 2-like 1 (GNB2L1), protein kinase C epsilon
(PRKCE), SWI/SNF related, matrix associated actin
dependent regulator of chromatin subfamily b, member 1
(SMARCB1), protein tyrosine phosphatase, non-receptor
type 11 (PTPN11), low density lipoprotein receptor
(LDLR), major histocompatibility complex class IA (HLA-
A), discs, large homolog 1 (Drosophila) (DLG1), polo-
like kinase 1 (PLK1) and colony stimulating factor 3
(CSF3). While the up-regulated gene nodes and related
pathways were mostly associated with cell cycle arrest,
induction of apoptosis (CASP3, CDKN1A) and DNA
repair (BRCA1, PCNA), the down-regulated gene nodes
were predominantly linked to control of cell cycle pro-
gression and cell proliferation
(CCND1,GNB2L1,SMARCB1,DLG1,PLK1), carbohydrate
and lipid metabolism (INSR, LDLR), intracellular signal-
ing (PRKCE, PTPN11), cell adhesion (ITGB1) and
immune response (HLA-A, CSF3). PPARA up-regulation
could also contribute to reduced metabolism rates in
treated spheroids by negatively regulating genes impli-
cated in carbohydrate (PKLR) and mostly lipid (ACOT8,
ACAA1, MGLL, PPARGC1B, DHCR24) metabolism (Fig-
ure 2).
Table 1: Characteristics of the six OC cell lines used in the study.
Cell type Source Histopathology IC50 values (μM)
cisplatin paclitaxel topotecan
OVCAR-3 tumor Adenocarcinoma 0,70 0,03 0,27
SKOV-3 ascites Adenocarcinoma 7,50 0,05 0,23
OV-90 ascites Adenocarcinoma 4,50 0,025 0,21
TOV-21 tumor Clear cell carcinoma 2,00 0,013 1,3
TOV-112 tumor Endometrioid carcinoma 3,50 0,016 0,25
TOV-155 tissue Cyst adenomaa 1,25 0,015 0,27
Treatmentb 10,0 μM 2.5 μM 5,0 μM
aUpon cultivation, the spontaneously immortalized TOV-155 cell line exhibited typical characteristics of an OC cell line (including p53 mutations, 
oncogene expression and continuous growth). The complete characterization of this cell line will be reported elsewhere.
bThe drug concentrations indicated were used for treatment of the OC spheroid cultures (details in text).Page 3 of 21
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Table 2: Selected common differentially expressed gene groups upon treatment with all drugs (cisplatin, topotecan and paclitaxel).
A. Up-regulated genes
Apoptosis BMF, CASP3, CASP7, EMP1, FADD, FOSL2, NOL3, PDCD2L, PERP, PHLDA2, ZNF443, BIRC3, BCL2A1
Cell adhesion BAIAP1, CELSR3, CLDN2, CLDND1, COL15A1, COL17A1, COL8A1, CSPG3, GJA10, OIP5, SSX2IP, SYMPK, 
TNXB
Cell growth and maintenance CDCA7, DCC1, KNTC2, NRG4, PRC1, SPATA5L1, TGFA, NOV
Cell cycle CNNM4, BUB1, CCNB2, CDC20B, CDCA2, CKS2, KIF23, PKMYT1, CDCA5, FLJ23311
Cytoskeleton ANXA9, C16orf5, CKAP2, K-ALPHA-1, KIAA1524, KIF18A, PALMD, SDCBP, SPTAN1, TUBB2, TUBB3, TUBB6
DNA replication and repair BRCA1, BRCA2, DDB2, FANCA, MCM10, MCM8, NP, PCNA, PTTG1, RPA3, POLA2, RRM1
Cell cycle arrest BTG3, CDKN1A, CDKN2D, GMNN, HIS1, RFP2
Regulation of transcription DAZL, DXYS155E, ELL2, HPS3, KLF5, LHX2, NR4A1, PER2, PHTF1, POLR2A, RFXAP, ST18, TAL2, TRIP13, 
ZNF211, ZNF304, ZNF326, ZNF483, ZNF529, ZNF541, ZNF550, ZNF555, ZNF646, ZNF701, ZIC4
Response to stress AHR, HSFY2, HSPH1, MICB, TXNDC, YWHAB
Intracellular signaling (signal 
transduction)
ASB3, AURKC, CALM2, CXXC4, DBF4B, DGKG, DKK1, DUSP8, DUSP9, EFNA3, FZD4, GPR109B, GPR6, IMP-1, 
MIP, MS4A3, NMI, NRAS, NYD-SP25, OR5P2, OR6K2, OR9I1, PDC, RAB21, RAB2B, RACGAP1, RGS13, RKHD3, 
SH2D1A, STMN1, STRN4, TAS2R60, WNT10A
Transport ABCC9, AQP11, ATP2B3, CACNB1, CHAC2, KCNJ9, MGC29671, NUP107, Shax3, SLC19A2, SLC25A17, 
SLC7A8, TRPM6, TXNL5, RAMP
B. Down-regulated genes
Apoptosis AIFM3, BCLAF1, DAPK3, DOCK1, FAF1, FKSG2, GADD45B, HIPK2, NALP12, NTN1, SPOCK, TNFRSF6B, YARS
Cell adhesion CASK, CD151, CIB3, CLDN18, CLDN5, CNTN4, GJC1, ITGB1, ITGB3BP, ITM2C, LAMA5, LOC388419, PKP4, 
PSTPIP1, PTK7, TNR
Cell growth and maintenance TBC1D5, CDC2L5, HDGF2, AKIP, AAMP, LRPAP1, MATK, PDAP1, PPARGC1B, SIPA1L3, TPD52L2, MT3, 
POLDIP2, POLDIP3, SET, ASCC3
Cytoskeleton ACTR1B, ARPC1A, ARPC4, CKAP1, CORO1B, DNAI2, FMNL1, KRT6C, PALM2, SPAG7, SPTBN5, TNK2, 
TUBGCP2, VILL, YWHAG
Response to stress CAMP, CEBPE, DEFB1, DEFQ1, GATA3, HSPA1A, HSPA12B, NOD27
Immune & inflammatory response ALCAM, AMBP, C1QB, C1QL1, C5, CD2BP2, COLEC11, HLA-A, HLA-B, HLA-E, HLA-F, IFI35, IGSF4, IL16, 
KIR3DL3, LAT, OAS3, R30953_1, RFX1, SAA2, TNFRSF13B, TREM1, CARD10, CCL19, EDARADD, LGALS9, SN
Lipid metabolism ACAA1, AKR1C3, APOE, ARH, ASAH1, CHKA, GPX4, HDLBP, HMGCS1, INPP5E, LDLR, MGLL, PCCB, PEMT, 
PIP5K2A, PLA2G12B, PLCB3, PRKAG1, PTE1
Metabolism (other than lipid 
metabolism)
ADH5, AK5, AKR1C1, ALDH4A1, ALDOA, ASMTL, ATAD4, B4GALT2, BCDO2, CA5A, CHST7, CYP11A1, DHPS, 
DHRS10, DOT1L, DPYD, ENO1, ENO1B, FBXW5, GAL3ST3, GMDS, GRHPR, HAAO, HCG9, HK2, HPD, 
IMPDH2, INSR, ISOC2, ITGB1BP2, ITIH2, LARGE, LEPREL2, MAT2A, MPPED1, MSRA, MVK, NAT6, NNMT, 
NUDT14, PGAM5, PHGDHL1, PKLR, PTPRG, PYGM, RDH13, SDHA, TKT
Protein biosynthesis & modification C19orf28, CRYL1, EEF1A2, EEF1D, EEF1G, EIF3S5, EIF3S8, EIF4B, EIF4G1, EIF5A, HAGHL, KRT6E, MRPL12, 
MRPL23, RPL10L, RPL6, RPS14, RPS19, RPS2, RPS9, VARS2, ANKRD13D, ATAD3A, ATAD3B, AFG3L2, ADCK1, 
ADCY5, BCKDK, CRYAA, DUSP15, FKBP10, FLOT1, GALNT9, HKE2, KIAA1542, MAP2K2, MTMR4, PARP10, 
PCTK2, PPP2R4, PPIB, SERPINH1, SIL1, SRPK2, SSTK, ST3GAL4, WNK2
Cell cycle CCND1, DLG1, DNM2, DDIT3, EXT1, MAD1L1, PLK1, PPP1R9B, SEPT2, STAG1
Regulation of transcription ARID3A, ASCL2, ATF4, CIRBP, CITED4, CORO1A, DBP, DEAF1, EWSR1, FOXQ1, GSCL, HES6, HMG20B, ING5, 
IPF1, KLF13, LBX1, MAF1, MBD3, MED25, MED31, MLLT1, NKX2-8, P4HB, PITPNM1, POLR1A, POLR2E, 
PRDM9, SEC8L1, SOX4, TBL1XR1, TCF25, TEAD2, TGFB1I4, VGLL4, ZFP276, ZFPM1, ZNF214, ZNF225, 
ZNF425, ZNF511, ZNF569, ZNF768, DHCR24, MXD4, TUFM
RNA processing RALY, SURF6, ARL6IP4, CPSF3L, DDX56, HNRPA2B1, HNRPAB, LOC144983, PABPC4, PARN, PSD, RPP40, 
SFRS5, SNRPB, SNRPN, U1SNRNPBP
Intracellular signaling (signal 
transduction)
AKT2, ANKRD23, ARHGEF15, ARL2, BRE, CABIN1, CKB, CSF3, CSNK1A1L, DHH, FZD1, GNA15, GNAQ, 
GNB2L1, GPR172B, GPR31, GPR32, GPR37L1, GPS1, GRAP, GRK1, GRM4, HRMT1L2, IGF2R, IL17R, INADL, 
JAK1, KSR2, MAP4K5, MAPK12, MAPK13, MAPKAPK2, MRAS, NMBR, NRTN, NSMCE1, NXF, OMP, OPN1LW, 
OPRD1, OR2T5, OR2Z1, OR8G5, OXT, PDHA2, PIK3R2, PIK4CA, PITPNC1, PKIG, PRKCSH, PTK9L, PTPN11, 
PTPRM, RAB3D, RHO, RHOC, RHPN1, RSU1, SRGAP3, STK25, PAC1BP3, TMEPAI, TNNT3, TRIM54, USH1C, 
VRK3, WNT3A
Transport ABCC4, ABCC6, ARL7, ATP1A3, ATP6V0E2, CACNG4, CHMP6, COL4A1, COX7A2L, CYBA, CYC1, ETFDH, 
EXOSC6, FMNL2, GABARAP, GRPEL1, HBM, HOXB8, ITPR2, ITPR3, KCNJ13, LMAN2, MGC19604, MLPH, 
MSCP, MYBBP1A, NBEA, NDUFS2, NDUFS6, PEX26, RAB1A, RALB, RAP2B, SCNN1D, SEC14L5, SEC24C, 
SEC61A1, SFXN4, SGNE1, SLC12A6, SLC17A6, SLC1A5, SLC25A24, SLC25A29, SLC25A6, SLC37A1, SLC6A8, 
SNX15, SNX17, SORT1, STX10, TIMM44, TLOC1, TMED9, TOMM40, TRAPPC6A, TRIAD3, TRPC5, TXN2, 
TXNRD1
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treatment with cisplatin, topotecan or paclitaxel
In parallel, we separately analyzed the gene expression
profiles in all six spheroid cultures following treatments
with each of the three drugs used (cisplatin, topotecan or
paclitaxel). The gene expression was compared between
control and treated spheroids, and a subset of differen-
tially expressed genes was selected displaying at least 1.5-
fold difference in four of the six microarray experiments
performed for each drug treatment.
Cisplatin treatment
Using these selection criteria, we found 205 genes to be
up-regulated and 363 genes to be down-regulated in OC
spheroids following cisplatin exposure [see Additional file
3]. Table 4 shows list of selected functional groups of
genes that were differentially expressed (≥1.5-fold) in the
cisplatin-treated spheroids. As seen from Table 4, up-reg-
ulated major functional gene groups comprised genes
mostly involved in cell growth and proliferation, control
of cell cycle (including cell cycle arrest) and DNA replica-
tion and repair. Down-regulated genes upon cisplatin
treatment were functionally associated with immune and
inflammatory response, metabolism, protein biosynthesis
and modification, RNA processing, signal transduction
and transport. Genes involved in cell adhesion, chromatin
organization, cytoskeleton structure and regulation of
transcription were predominantly suppressed following
cisplatin exposure. Apoptosis genes were proportionally
up- and down-regulated.
The above data were further confirmed by pathway and
network analyses. Indeed, major functional gene catego-
ries that were specifically up-regulated in cisplatin-treated
OC spheroids included cellular assembly and organiza-
tion, cell death and DNA replication, recombination, and
repair (Figure 1B). Pathways associated with metabolism,
molecular transport, protein synthesis and trafficking
were down-regulated, while pathways linked to cell
growth and proliferation, cell cycle and cell signaling dis-
played altered regulation (Figure 1B). Network analysis
identified 21 highly significant networks with score ≥ 9
[see Additional file 4]. The 5 top-scoring networks found
in cisplatin-treated OC spheroids were associated with cell
Functional analysis for a dataset of differentially expressed genes (≥1.5 fold) in OC spheroids following CT drugs treatmentsigure 1
Functional analysis for a dataset of differentially expressed genes (≥1.5 fold) in OC spheroids following CT drugs treatments. A. 
Functional analysis following all drugs (cisplatin, topotecan and paclitaxel) treatment, B. Functional analysis following cisplatin 
treatment. Top functions that meet a p-value cutoff of 0.05 are displayed.
A.    
Up-regulated upon all drugs treatment                              Down-regulated upon all drugs treatment
B.    
Up-regulated upon CIS treatment                                    Down-regulated upon CIS treatmentPage 5 of 21
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Ntwk Genes in Ingenuity networksb Associated pathways Scorec
A. Networks, commonly affected by treatment with all drugs (cisplatin, topotecan and paclitaxel)
1 ARL2, ARL6IP, ATAD2, BUB1 (includes EG:699), CDKN1A, CEP55, CTH, DEAF1, DTL, EIF5A, 
FHIT, HES6, HIST1H1B, HNRPA2B1, HOXA10, ING5, KIAA0101, KIF23, KIF2C, NUSAP1, 
PBK, PKMYT1, PLK1, PRC1, PSAP, RACGAP1, SORT1, SPDEF, TBCD, TUBB3, TUBB2A, 
UBE2S, UBE2T, UHRF1, VGLL4
Cell Cycle, Cellular 
Movement, Cancer
43
2 BIRC3, BRE, CASP3, CASP7, CEBPE, CSF3, CTSD, DLC1, DNM2, EDA, EIF4B, EIF4G1, EMD, 
ENO1, FADD, FANCA, GPX4, GRK1, IGF2R, IL17RA, KNTC2, LAMA5, LMNA, MAD1L1, 
PLSCR1, PRKCE, PTMA, RHO, SNCG, SPBC25, SPTAN1, TNFRSF6B, TRIM63, TXNL5, 
ZWINT
Cell Death, Connective 
Tissue Disorders, Cellular 
Growth and Proliferation
43
3 ADCY2, AHR, ALCAM, APOE, ASCL2, CASK, CCND1, CDKN2D, COX7A2L, CRYL1, DBP, 
DKK1, DLG1, DLL4, F11R, FZD1, FZD4, GMNN, KLF5, LDLR, LDLRAP1, LRPAP1, MCM10, 
MDFI (includes EG:4188), MRAS, PER2, PLXNB2, PPP2CB, PPP2R4, SET, SMARCB1, 
SMARCD2, SNX17 (includes EG:9784), WNT1, WNT3A
Gene Expression, Lipid 
Metabolism, Small Molecule 
Biochemistry
43
4 AKT2, BRCA1, BRCA2, C5, CA5A, CD151, DDB2, DDIT4, GNB2L1, HMG20B, IFI35, ITGB1, 
ITGB1BP2, JAK1, LRCH4, NMI, NOV, NRAS, NTN1, PERP (includes EG:64065), PIK4CA, 
PITPNM1, PPP1R2, PPP1R9B, PTPN11, PTPRM, SERPINH1, SH2D1A (includes EG:4068), 
SLAMF1, SLC7A8, SNAI2, TMED9, TNFAIP2 (includes EG:7127), XRCC6, YWHAB
Cell Death, Cancer, Cell 
Cycle
43
5 ACAA1, ACOT8, B2M, CTSL2, DHCR24, GADD45B, HIPK2, HLA-A, HLA-B, HLA-E, HLA-F, 
HMGA1, IL22RA2, INSR, MGLL, MVK, MYBBP1A, NALP12, PCNA, PFDN6, PIK3R2, PKLR, 
POLDIP2, PPARA, PPARGC1B, PSMB8, PTPRG, RFX1, RFXAP, RRM1, SFRS5, SNX15, SURF6, 
TOMM40, TUB
Nutritional Disease, Cancer, 
Lipid Metabolism
43
B. Networks, affected by cisplatin treatment
1 BRCA1, CEBPE, CLU, DDIT4, ECE1, EEF1D, ENO1, EPPB9, GATA3, HIPK2, LDLR, LDLRAP1, 
LTBP3, MAD1L1, MAPKAPK2, MGMT, MSH2, MXD4, PDZK1IP1, PERP (includes EG:64065), 
PKIG, PLSCR1, PRKCG, PSMC3, PSMD12, RAG2, RHO, SMAD3, SPHK1, STOML2, TGFB1, 
TGIF, TMEPAI, TNFAIP2 (includes EG:7127), XRCC6
Cell Cycle, Cancer 51
2 ATAD2, CDC2, CDKN1A, CHAF1B, DKFZP762E1312, DNMT1, DTL, EXO1, FHIT, HES6, 
HOXA10, ING5, KIAA0101, MCM2, MCM3, MCM4, MCM10, MYBBP1A, NUSAP1, PBK, 
PCNA, PIP5K1C, PKMYT1, PSAP, RACGAP1, RRM1, RRM2, RUVBL2, TYMS, UBE2A (includes 
EG:7319), UBE2S, UBE2T, UHRF1, VGLL4, WDHD1
DNA Replication, 
Recombination, and Repair, 
Cancer
51
3 APAF1, APIP, AVEN, BCL2A1, BDNF, BIN1, BIRC1, CASP3, CASP7, CSH2, CTSD, DBNL, DEDD, 
DFFA, DLC1, DNM2, EIF4G1, EIF4G3, FADD, GAS2, GPX4, HCRT, HSH2D, ITGB3BP, LTBR, 
MAP2K5, PDE4A, PINK1, PRKAA2, PRKCZ, PSAP, SNCG, STK11, TGFA, TNFRSF6B
Cell Death, Cancer, 
Hematological Disease
21
4 BRD2, C19ORF2, CREB1, CYP11A1, EP300, EWSR1, EXOSC6, FUSIP1, GAS2L1, HLA-G, HSPA4L, 
ITM2C, LSM7, MYH13, MYOD1, NFYB, NUDT2, POLR1A, POLR2A, POLR2E, POLR2F, RRN3, 
SENP1, SIAHBP1, SUPT3H, TAF1C, TBP, TEAD2, TEAD4, TKT, TNNC1, TNNI2, TNNT2, TRERF1, 
VGLL1
Gene Expression, Cell Cycle, 
Skeletal and Muscular System 
Development and Function
20
5 ALAS1, ALPP, ARPC5, CD244, CD2BP2, CTH, CUGBP2, DNAJB5, EDF1, EGR2, EPS8L2, ERG, FOS, 
GRM4, HDLBP, HLA-B, HOXA9, IL1RL1, JUB, JUN, KEAP1, NFE2L2, NIPSNAP1, NTS (includes 
EG:57303), PMP22, RPS9, SDCBP, SKIV2L, SNCG, SNRPB, SOS1, USP1, WBP4, WDR90, WT1
Gene Expression, Organismal 
Injury and Abnormalities
18
C. Networks, affected by topotecan treatment
1 ARL6IP, ASPM, ATAD2, CDKN1A, COG1, COG5, CRI2, DDB2, DEAF1, DLG7, FHIT, H2AFZ, 
HES6, HIST1H1B, HNRPA2B1, KIF2C, KLF5, LIG3, MLLT1, NEIL1, NUSAP1, PARP2, PLK2, 
PSAP, RACGAP1, SET, SPDEF, SUPT16H, TRIM44 (includes EG:54765), UBE2C, UBE2D1, 
UBE2S, UBE2T, UHRF1, VGLL4
DNA Replication, 
Recombination, and Repair, 
Cell Cycle, Cellular 
Compromise
41
2 ADCY2, ADCY5, AKT1, ASCL2, CCL19, CCND1, CDH2, DKK1, DLC1, DLG1, DLG2, DLL4, 
FZD1, FZD4, GNAI1, GNB1, GNB2L1, H2AFX, MDFI (includes EG:4188), MRAS, NEUROG1, 
NEUROG3, NRAS, PRKAG1, PRKAR1A, PTPRM, RASSF1, ROBO1, SEMA3C, SRGAP1, TBCD, 
TUBB3, TUBB2A, WNT1, WNT3A
Cellular Movement, Cancer, 
Reproductive System Disease
41
3 AMPH, BRE, CABIN1, CALM1, CASP3, DAPK1, DDEF1, DNM2, DOCK1, EIF4B, EIF4G1, 
EIF4G3, ENO1, EPN1, EPS15, GNLY, GRK1, LMNA, MAP4K3, PTK2, PTMA, RHO, RIT2, 
SNCG, SPHK1, SPTAN1, SPTBN1, STK3, SYNE2, TNFRSF6B, TPD52L1, TPD52L2, TRIO, 
TXNL5, WASF1
Cellular Assembly and 
Organization, Cellular 
Function and Maintenance, 
Cellular Movement
41
4 ALDOA, ANP32B, B2M, BRF1, CALR, CAMK1, CKB, CLIC4, CORO1A, ELAVL1, FN1, 
GABARAP, HLA-A, HLA-B, HLA-E, IGF1R, ITGB5, ITGB3BP, ITSN1, KPNA2, KRT8, MAPK7, 
MEF2A, NALP12, NTN1, NUMB, PTPN11, PTPN3 (includes EG:5774), RAB1A, RAN, 
SLC2A4RG, SND1 (includes EG:27044), VCL, YWHAB, ZAK
Protein Trafficking, Cell 
Death, Molecular Transport
41
5 ACTL6A, ACTL6B, ARID1B (includes EG:57492), CCNB2, CDC2, CDK8, CEP170, CGA, CTSL2, 
GMNN, HMGA2, IFITM2, IFNGR1, INSR, ISGF3G, JAK1, MED25, NEK2, PKMYT1, PLK1, 
PLXNB2, PRKCZ, PSMA4, PSMB7, PTPRG, PTTG1, RAD51AP1, RNF103, SFRS5, SLC9A3R1, 
SMARCB1, SMARCD2, SNX15, SURF6, TUB
Cell Cycle, Cellular Assembly 
and Organization, Cancer
41
D. Networks, affected by paclitaxel treatmentPage 6 of 21
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cancer and altered gene expression (Table 3B). A common
network obtained upon merging the three top-scoring
networks identified some shared nodes found upon treat-
ment with all drugs (CDKN1A, BRCA1, CASP3, PCNA; see
above), as well as several specific cisplatin exposure-
related nodes implicated in apoptosis and cell cycle con-
trol, including cell division cycle 2 (CDC2), SMAD, moth-
ers against DPP homolog 3 (SMAD3), minichromosome
maintenance deficient 2, mitotin (MCM2) and transform-
ing growth factor beta 1 (TGFβ1) (Figure 3).
Topotecan treatment
Three hundred and sixty genes were up-regulated and 663
genes were down-regulated at least 1.5 fold in topotecan-
treated OC spheroids [see Additional file 5]. A list of
selected functional categories of differentially expressed
genes (≥1.5-fold) in topotecan-treated spheroids is shown
on Table 5. As seen in Table 5, genes functionally related
to apoptosis, cell growth and proliferation, cell cycle con-
trol, cell adhesion, cytoskeleton, DNA replication and
repair and defense (stress) response, displayed compara-
tive up- and down-regulation upon topotecan treatment.
Genes implicated in cell cycle arrest, and protein ubiquiti-
nation were predominantly overexpressed, while genes
linked to chromatin modification and maintenance,
immune and inflammatory response, metabolism
(including lipid metabolism), protein biosynthesis and
modification, signal transduction and molecular trans-
port, were mostly down-regulated (Table 5).
IPA validation of biological functions and networks that
were most significant to the topotecan microarray data set
were in agreement with our initial gene expression data.
As shown on Figure 4A, functional pathways implicated
in cell growth and proliferation, cell cycle, cell death, cell
signaling, DNA replication, recombination and repair and
protein synthesis displayed significant altered expression
in both directions. Positively induced pathways com-
prised those linked to cellular assembly and organization
and cellular response to therapeutics, while functional
pathways that were subject to down-regulation in topote-
can-treated OC spheroids were associated with cell-to-cell
signaling and interaction, metabolism, immune response,
protein trafficking and molecular transport (Figure 4A).
Thirty highly significant networks with score ≥ 9 were
identified by network analysis [see Additional file 6]. The
five top-scoring networks were functionally associated
with DNA replication, recombination, and repair, cellular
assembly and organization, cell cycle, cellular movement,
cell death, protein trafficking and molecular transport
(Table 3C). A common network was obtained upon merg-
ing the five top-scoring topotecan-related networks (Fig-
ure 5), which recognized some nodes found also in the
all-drugs-treatment networks (CDKN1A, CASP3 (up-regu-
lated), and CCND1, SMARCB1, INSR, PTK2, HLA-A,
PTPN11 (down-regulated) and in the cisplatin-treatment
network (CDC2). Additionally, the network analysis iden-
tified specific topotecan-related down-regulated gene
nodes that include v-akt murine thymoma viral oncogene
homolog 1 (AKT1), protein tyrosine kinase 2 (PTK2),
wingless-type MMTV integration site family, member 1
(WNT1), insulin-like growth factor 1 receptor (IGF1R),
fibronectin 1 (FN1) and calreticulin (CALR). These nodes
comprise genes, mainly associated with cell cycle progres-
sion and cell proliferation (AKT1, WNT1, IGF1R), cell
adhesion (FN1, CALR) and cell invasion (PTK2).
1 BAG5, CTNNB1, CTNNBIP1, FZD8, GSTP1 (includes EG:2950), H2-ALPHA, JRK, K-ALPHA-1, KIF23, 
KLK2, LOC112714, LRP6, MDFI (includes EG:4188), MRPL13, MT3, MYF5, PARK2, PLK1, 
PTP4A3, RBP4, SERPINA5, TPT1, TUBA1, TUBA2, TUBA3, TUBA6, TUBA8, TUBB, TUBB1, TUBB3, 
TUBB4, TUBB2A, TUBB2C, TUBG1, WNT3A
Cancer, Reproductive System 
Disease, Renal and Urological 
Disease
22
2 ALOX5AP, ASAH2, CEBPE, CEBPG, DDIT3, DHPS, DNAJB5, DUSP9 (includes EG:1852), EIF4G1, 
ELK4, ERN1 (includes EG:2081), G6PD, GCLC, GCLM, IL3, IMPDH2, LAT, LCN2, MAPK12, MKNK1, 
MKNK2, MMP8, MT2A, NFE2L2, PRG2 (includes EG:5553), RPS6KA5 (includes EG:9252), SLC5A5, SLK, 
TALDO1, TDRD7, TGIF, TLR9, TNF, WNT10A, ZBTB17
Drug Metabolism, Molecular 
Transport, Small Molecule 
Biochemistry
19
3 ARPC1A, ARPC1B, BAX, BIRC6, CCNL2, CXCL13, DDIT4, EIF5A, FFAR3, GATA3, GPR44, HLA-A, 
HLA-E, HNRPA2B1, HOXC11, HSD17B1, ING5, JMY, LETMD1, LMNA, LTB, LTBP1, MDH1, 
MDM4, NALP12, PEG3 (includes EG:5178), PPP1R13B, PYCARD, RALY, SERPINB5, STK11, TBX21, TP53, 
TP53INP1, VHL
Cancer, Cell Death, Skeletal 
and Muscular Disorders
19
4 AHNAK, ANP32B, BAK1, C19ORF10, CAMP, DBP, DDIT3, ELAVL1, ENO2, FCGR2A, FCGR2B, HLA-C, 
HNRPA2B1, HRAS, IFI202B, IFNG, IL6, IL24, IL1RL1, LGALS1, LY6E, MOG, PLCE1, PSMB9, PSMB10, 
PTMA, S100A10, SDHA, SIRPA, TAP1, TFG, TNFRSF10B, TNFRSF6B, TRIM21, TTC28
Connective Tissue Disorders, 
Inflammatory Disease, Cell 
Death
17
5 ATF6, ATP5B, BZRAP1, COL1A1, COX4I2, COX5B, COX6A1, COX6A2, COX6B1, COX6B2, COX7A2L, 
COX7B, COX8C, CREBL1, DBI, GATAD2B, HDAC1 (includes EG:3065), ITM2C, LY6A, MBD3 (includes 
EG:53615), MBD3L1, MRPL12, MT1A, MYC, NFYB, PLK1, PRRG2, RAB3D, RIMS1, RIMS2, TRAM2, 
TSPO, TXNIP, UBE2S, ZBTB16
Cancer, Gene Expression, 
Tumor Morphology
17
aThe five top-scoring networks for each drug treatment are presented.
bBold genes are those identified by the microarray analysis, other genes were either not on the expression array or excluded by our gene expression 
selection criteria.
cA score of 3 was considered significant (p < 0.001).
Table 3: Genetic networks in CT drugs-treated OC spheroidsa. (Continued)Page 7 of 21
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We found 126 genes to be up-regulated and 139 genes to
be down-regulated at least 1.5 fold in paclitaxel-treated
OC spheroids [see Additional file 7]. Table 6 shows list of
selected functional groups of these genes. Thus, up-regu-
lated genes upon paclitaxel exposure are implicated in
Network analysis of dynamic gene expression in OC spheroids based on the 1.5-fold common gene expression list obtained follo ing treatment with all CT drugs used (cisplatin, topotecan and pacli axel)Figure 2
Network analysis of dynamic gene expression in OC spheroids based on the 1.5-fold common gene expression list obtained 
following treatment with all CT drugs used (cisplatin, topotecan and paclitaxel). The five top-scoring networks were merged 
and are displayed graphically as node (genes/gene product) and edges (the biological relationships between the nodes). Intensity 
of the node color indicates the degree of up- (red) or downregulation (green). Nodes are displayed using various shapes that 
represent the functional class of the gene product (square, cytokine, vertical oval, transmembrane receptor, rectangle, nuclear 
receptor, diamond, enzyme, rhomboid, transporter, hexagon, translation factor, horizontal oval, transcription factor, circle, 
other). Edges are displayed with various labels that describe the nature of relationship between the nodes: ---- binding only, → 
acts on. The length of an edge reflect the evidence supporting that node-to-node relationship, in that edges supported by arti-
cle from literature are shorter. Dotted edges represent indirect interaction.Page 8 of 21
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(including a number of tubulin genes), while down-regu-
lated functional groups comprised genes linked to cell
growth and proliferation, immune response and tran-
scription regulation. Comparatively high number of genes
with similar function displayed proportional up- and
down-regulation upon paclitaxel treatment, and more
specifically, genes related to cell cycle control, metabo-
lism, protein biosynthesis and modification, signal trans-
duction and transport. Network analysis identified up-
regulated functional pathways linked to cellular assembly
and organization, cell death and protein synthesis, while
down-regulated pathways included cellular growth and
proliferation, control of gene expression, and protein traf-
ficking. Pathways, associated with cell cycle, metabolism,
transport and cell signaling displayed comparative altered
expression in both directions (Figure 4B). Eleven signifi-
cant networks were identified following paclitaxel expo-
sure [see Additional file 8], and the five top-scoring
pathways were mostly associated with cancer, cell death,
drug metabolism, gene expression, molecular transport
and inflammatory disease (Table 3D). A common net-
work obtained upon merging the three top-scoring net-
works identified the pro-apoptotic BCL2-associated X
protein (BAX) node and several tubulin genes, that were
up-regulated upon paclitaxel treatment, as well as a
number of differentially expressed genes linked with the
p53 and the tumor necrosis factor (TNF) pathways (Figure
6).
Association of gene expression patterns with spheroid's 
morphology
The six OC cell lines used in this study displayed different
morphology when grown as spheroids, forming rather
compact spheroids (derived from OV-90, OVCAR-3,
SKOV-3), or more loose structures or aggregates (derived
from TOV-112, TOV-21, TOV-155; examples for both
spheroid structures are shown on Figure 7A). As expected,
Table 4: Selected differentially expressed gene groups upon cisplatin treatment.
A. Up-regulated genes
Apoptosis DNAJA3, EMP1, PERP, PHLDA2, ZNF443, BCL2A1, APAF1, CASP3, CASP7, FADD, PPP2CA
Cell growth and proliferation DSN1, MIS12, MND1, SPATA5L1, DCC1, HELLS, ANXA1, NUSAP1, Spc25, TGFA, TYMS, UHRF1, EZH2
DNA replication and repair BRCA1, CHAF1B, EXO1, MSH2, NEIL3, PCNA, POLQ, RAD51AP1, UBE2A, PRIM2A, MCM10, MCM2, MCM3, 
MCM4, POLA2, POLE3, PRIM1, RRM1, RRM2
Cell cycle ZWINT, SEPT10, CDC2, CDC45L, CDCA5, CNNM4, E2F8, GNL3, PKMYT1, PPP6C
Cell cycle arrest BTG3, CDKN1A, GMNN, HIS1, RECK, CDKN2D
Cell adhesion CLDN2, TNXB, GJA10, EMP1, ANKRD32
Cytoskeleton PALMD, SDCBP, ANKRD27
Regulation of transcription C16orf34, CBFB, CREM, ELL2, MORC3, NR4A1, PHTF1, RRN3, TRIP13, WDHD1, ZBTB38, ZNF180, ZNF211, 
ZNF26, ZNF304, ZNF326, ZNF45, ZNF529, ZNF550, DNMT1, EED, TGIF, LHX2
Signal transduction ALS2, ARL6IP6, DEPDC1, JUB, NOC3L, RAB21, RAB2B, RACGAP1, SLAMF1, SMAD3, STMN1, STRN4
Transport C20orf35, CACNB1, GPD2, MFTC, NUP107, PSCD1, SCN2B, Shax3, SLC19A2, SLC25A17, SLC25A17, THOC4
B. Down-regulated genes
Apoptosis CARD9, DAPK3, DOCK1, GP9, LTBR, YARS, PRKCZ, TNFRSF6B, DDIT4, CLU, HIPK2, NME3, NUDT2
Cell adhesion BCLAF1, CCDC78, CD151, ITGB3BP, LAMA5, LIMS2, MUC6, SN
Chromatin organization H1FX, HIST1H1E, HIST1H2AA, HIST1H3G, HIST1H3H, HMG20B, SAFB
Cytoskeleton ACTR1B, CYLN2, DLC1, DNAI2, EML3, TMEM102, KRT6E, ODF2, PDLIM2, SPTBN5, TUBGCP2, VILL
Immune & inflam-matory response C1QL1, CD2BP2, CIB3, COLEC11, HES6, HLA-B, HLA-C, HLA-E, HLA-G, KIR3DL3, LAT, OAS3, OTUB1, IRGC, 
RFX1, TNFRSF13B, NIBP
Lipid metabolism ARH, HDLBP, LDLR, LOC197322, PEMT, AGPAT2, CYP11A1, PCCB, PSAP
Metabolism (other than lipid metabolism) AKR1C3, ALDOA, B4GALT2, CA5A, CDC42EP1, CLYBL, DHRS10, ENO1B, GMDS, GRHPR, HAGHL, HPD, 
HSD11B1, HYAL2, IMPDH2, ITIH2, LARGE, LHPP, NDST2, NUDT14, OGDH, P4HB, PRLH, PSMC3, PYGM, 
RDH13, ST6GALNAC6, TKT
Protein biosynthesis & modification ASMTL, C9orf54, CRYL1, EEF1A2, EEF1D, EIF4G1, HOXB8, MRPL12, RPL18, RPS14, RPS2, RPS9, SURF6, TUFM, 
VARS2, PPP2R4, DUSP15, CKAP1, FKBP2, HKE2, PPIB, ST3GAL3, ADCK1, STK11, KIAA1542
Regulation of transcription PRDM9, ANKRD23, ARID5A, ASCL2, CHST7, COMMD4, DUX4, ENO1, EWSR1, FOXQ1, HLA-A, HOXA10, 
IL17R, ING5, KEAP1, LBX1, LTBP3, MBD3, MED25, MLLT1, MXD4, MYBBP1A, POLR1A, POLR2E, SIAHBP1, 
SLC6A8, SUPT3H, TEAD2, VGLL4, ZNF511, ZNF607
RNA processing C20orf14, CPSF3L, DDX49, DHX30, EXOSC6, HNRPAB, LOC144983, MARS, PARN, PPAN, RNASET2, SNRPB, 
ARL6IP4, CIRBP
Signal transduction ADCY2, ADCY5, CABIN1, CALML5, CAMK1, DDEF1, DLL4, EPN1, FZD1, GNA15, GPR37L1, GRAP, GUK1, 
ITGB1BP2, JAK1, KSR2, MAP2K5, MAPBPIP, MAPKAPK2, NRTN, NSMCE1, OMP, OR2T5, OR2Z1, PIP5K1C, 
PKIG, PRKCG, PSD, PTPRM, RAP2B, RHO, SPHK1, STOML2, TMEPAI, WNT1
Transport ABCC6, ASNA1, BC-2, CACNA1B, CCS, CORO1A, CYBA, DOT1L, ETFDH, FLJ11749, GRIN2D, HBM, LMAN2, 
MGC19604, MSCP, NDUFS2, NDUFS6, PP784, SCNN1D, SEC24C, SEC61A1, SEC8L1, SLC12A6, SLC25A29, 
SLC25A6, SLC2A11, SLC37A1, SNX15, STX10, SYNGR2, TRAPPC6A, GRM4Page 9 of 21
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BMC Genomics 2008, 9:99 http://www.biomedcentral.com/1471-2164/9/99a higher number of genes displayed differential expres-
sion upon CT drugs treatment in the aggregates than in
the compact spheroids (data not shown). These structure-
associated gene expression differences were further con-
firmed by cluster analysis. Indeed, supervised clustering
based on a selected list of 85 genes revealed formation of
two major cluster groups that perfectly distinguish
between compact and aggregate structures (Figure 7B).
Genes implicated in cell adhesion (CSPG3, ITGAV,
MUC1), negative regulation of cell proliferation (GPNMB,
MXD4) and metabolism (FGF14, CDC42EP1, IGFBP4,
GNA15, ARL7, HRMT1L1, LRDD, OR2A1) were compara-
tively up-regulated in the compact spheroids, while genes
associated with cell proliferation (ERBB4, ADRA1B,
Network analysis of dynamic gene expression in OC spheroids based on the 1.5-fold common gene expression list obtained follo ing cisplat n treatmentFigure 3
Network analysis of dynamic gene expression in OC spheroids based on the 1.5-fold common gene expression list obtained 
following cisplatin treatment. The three top-scoring networks were merged and are displayed graphically as nodes (genes/gene 
products) and edges (the biological relationships between the nodes). Figure legends are as described in Fig. 2.Page 10 of 21
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A. Up-regulated genes
Apoptosis PERP, BAG2, NOL3, PDCD2L, PHLDA2, THAP2, TEGT, CASP3, CASP7, SCOTIN, SMNDC1
Cell growth and proliferation ASPM, CDCA1, DDX11, KIF2C, MAD2L1BP, NEK2, PLOD3, CALM1, CALM2, CDC2, CSRP2, RARRES3, CDCA5, 
NUSAP1, CTBP2
Cell cycle C14orf11, CCDC5, CCNB2, CDC37L1, CDCA2, CKS2, CNNM4, PKMYT1, SNF1LK, TIMELESS, UBE2C, UHRF1, 
ZWINT, PLK2, SERTAD1
Cell cycle arrest BTG3, CDKN1A, CDKN2D, HIS1, MFN2, PPM1G, TRIM13, PPM1D
Cell adhesion ANXA9, GJB1, STRN4, TFPI2, TNXB, GJA10, PCDHB16, C3orf4, CLDN1, CLDN2, ANKRD32
Cytoskeleton ANXA9, CFL2, CKAP2, KRT8, SDCBP, SLC9A3R1, SPTAN1, TUBB2, TUBB3, WASF1
Defense response APOBEC3B, CAMLG, UPK3B, ARS2, AHR, HSPA4L, HSPH1, SELS
DNA replication and repair C1orf124, CRY2, DDB2, NEIL1, PCNA, PTTG1, RAD51AP1, TDG, DUT, POLA2, POLG
Metabolism ACOX1, CDS1, ELOVL4, GALGT2, PLA2G4C, PLSCR1, ADIPOR1, GOT1L1, ABHD13, ABHD3, ADHFE1, ARPP-19, 
GLA, GLS2, GYG2, IDS, PGM2, PGM2L1, PPP1R2, PSMA4, RP2, TEX261, DCK, OBFC2A
Protein biosynthesis & modification ARL6IP, EIF4H, FAM83D, MRPL52, MT-ND3, RPL39, RPLP1, RPS13, RPS29, PPP2CB, PTP4A3, BBS10,, DNAJA5, 
DNAJB5, DNAJC9, NKTR, PPIC, FUT11, ICMT, KIAA1804, PARP2
Ubiquitination CBLL1, DTX3L, FBXO5, HSPC150, LOC51136, MYLIP, RFFL, RNF139, RNF6, TRIM21, UBE2D1, UBE2C
Regulation of transcription SAFB2, TUB, BACH1, BRD8, C7orf11, CCRN4L, CNOT8, DXYS155E, E2F8, FOXA3, GTF2B, KLF5, LHX2, 
NR4A1, OSR2, PLAGL2, POLR2A, SAP18, SMYD1, SOX10, SOX9, ST18, SUHW3, SUPT16H, SUZ12, TAF12, 
YEATS2, ZNF211, ZNF318, ZNF326, ZNF92, DNMT1, EED, GMNN, TCEAL1
RNA processing CSTF2T, DBR1, DDX20, DDX48, FRG1, HEAB, KHSRP, LARP6, PRPF39, RBM26, SF3B4, SLBP, SLU7, ZCCHC8
Signal transduction CABYR, CGA, DKK1, DLG7, DUSP9, DYRK3, FZD4, IER5, MAPK7, NRAS, OR7E91P, PRKAR1A, RAB2B, RACGAP1, 
RASSF1, RIT2, RKHD3, RUSC1, STMN1, STRN4, TFPI2, TP53TG3, YWHAB
Transport AMPH, APBA3, ATP2B3, CLCC1, COG1, CYP2R1, DYNLT1, GGA3, KCNJ9, KCTD10, KPNA2, LAPTM4A, NDUFB2, 
NETO2, RBM8A, RINT-1, SCN2B, Shax3, SLC19A2, SLC25A17, SLC25A4, SLC9A6, SMOX, TRAM1, TRAPPC4, 
TXNL5, WDR48, YIF1
B. Down-regulated genes
Apoptosis APP, CRYAA, DAPK1, DAPK3, DNM2, DOCK1, FAF1, GULP1, NALP12, TNFRSF12A, TNFRSF6B, WDR9, YARS, 
BCL2L2, FKSG2, PRKCZ, AIFM3, BCLAF1
Cell adhesion ALCAM, CASK, CD151, CDA08, CDH2, CLDN18, EIF4G1, FARP1, GJC1, ITGB5, LAMA3, LAMA5, LAMB1, PKP4, 
ROBO1, SN, TNR, VCL
Cell growth & proliferation NEK7, CTDSPL, HDGF2, IGF2R, NPDC1, CKLFSF2, AAMP, PRKD1, IL27, NIPSNAP1, PDAP1, PEMT, TPD52L2, 
ZMYND11, MXD4, IGF1R, LRP16, MT3, MOBKL2B
Cell cycle CCND1, PCTK2, SEPT6, CDK6, CDK8, CHES1, PLK1, STAG1, EXT1, FHIT
DNA replication and repair DDIT4, ECGF1, ERCC8, FBXO18, LIG3, MGMT, PRKDC, POLDIP3, SET
Chromatin modification & maintenance ACTL6B, ANP32B, CHD6, HDAC3, HDAC8, HIST1H1B, HIST1H1E, HIST2H2AC, SAFB, H1FX, HUWE1, 
SMARCD2, KIAA1797
Cytoskeleton ARPC1A, C9orf140, CENTG2, CEP170, CYLN2, DIAPH2, DLC1, DLG1, DNCH2, FHOD3, FMNL2, GRM4, ITGB1, 
KIF21A, MGLL, MID1, ODF2, SNCG, SPIRE1, SPTBN1, SPTBN5, SVIL, ARPC4, FMNL1
Defense response CBARA1, DEFQ1, GATA3, GNLY, HSPA12B, NOD27, AHSA1, OXR1, STIP1, STK25, STK3, STK39, TLK1, ZAK, 
GADD45B
Immune & inflam-matory response AMBP, C1QL1, COLEC11, D2S448, EIF3S8, FN1, HLA-A, HLA-B, HLA-E, IGSF4, IGSF4C, KIR3DL3, MCP, RFX1, 
RSRC1, TREM1, CCL19
Lipid metabolism PRKAG1, ACAA1, ARH, CHKA, CRYL1, HMGCS1, INPP5E, LDLR, SBF2, SREBF2, HADHA, CRYL1, DHCR24, 
HDLBP, PIP5K2A, PITPNM1, PSAP
Metabolism (other than lipid metabolism) INSR, GANAB, ABHD14B, ACO2, ADK, ADK, AK5, ALDH4A1, ALDOA, ASMTL, B4GALT2, BCDO2, C10orf110, 
C3orf26, CA5A, CKB, COG5, CROCC, DHRS10, DHRSX, DHRSX, GBE1, HAGHL, HARS2, HHAT, HIBADH, 
HS3ST3A1, ITIH2, KIAA0100, LARGE, MAT2A, ME1, ME1, MSRA, MVK, NUDT14, NUDT2, PDHA2, PDSS2, 
PGAM5, PGD, PHGDHL1, PHKB, PIK4CA, PMM2, PPP1R9A, PSMC3, PYGM, raptor, RDH13, SDHA, 
ST6GALNAC6, SULF2, SUMF1, ACBD6, TIMM44
Protein biosynthesis & modification ADCY5, EIF2S3, ELP4, LAT, MARS, MRPL12, MRPL12, MRPL23, MRPL28, PARN, RPL10L, RPL22, RPL36, RPL6, 
RPS14, RPS2, RPS9, RRBP1, SURF6, TUFM, VGLL4, WARS, EEF2, EIF4G3, ATAD3B, BCKDHB, BMPR1A, CDC14B, 
CKAP1, CYP11A1, DUSP15, FLOT1, IMMP2L, KIAA1542, PAM, PPP2R4, TRIAD3, TRIO, UGCGL2, WNK2, PTPN3, 
PTPRK, PTPRM, FNTB, CCT7, FKBP8, FKBP9, PPIB, TBCD, ST3GAL4, RFWD2, TTC3
Proteolysis & peptidolysis ADAM9, ADAMTS7, AFG3L2, CAPN5, COH1, CPD, CTSL, DPP7, PRSS15, PRSS8, PSMB7, PSMB9, SERPINB11, 
SERPINH1, SIPA1L3, SPPL3, TSP50
Regulation of transcription TCF25, ADCY2, ARID1B, ARID3A, ASCL2, ATF4, BAZ2B, BBX, BCL6B, BRF1, CALR, CEBPE, COMMD10, DBP, 
DEAF1, EEF1A2, EWSR1, FOXQ1, HERC2, HES6, HMGA2, IPF1, ITGB3BP, KLF13, LBX1, MED25, MLLT1, 
MTA1, POLR2E, PRDM9, PSD, PTK2, SLC2A4RG, SMARCA3, SMARCB1, SND1, SOX4, SPDEF, SUPT3H, 
TBL1XR1, TCF12, TCF8, TEAD2, TEAD4, TGFB1I4, TRPS1, ZFP3, ZNF768, MLLT3, ZFPM1, ZNF193, ZNF214, 
ZNF271, ZNF306, ZNF503, ZNF511, ZNF521, ZNF543, ZNF569, MAFK
RNA processing ARL6IP4, CIB3, DDX10, DDX49, DDX56, EIF4B, ENO1B, EXOSC6, HNRPA2B1, HNRPAB, HNRPUL1, KARS, 
LOC144983, NARS2, PABPC4, QKI, RALY, RNASET2, RNGTT, RPP40, SFRS5, SNRPB, SNRPNPage 11 of 21
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modification (DUSP21, FLJ23356, HSPA1A) were pre-
dominantly up-regulated in aggregates [see Additional file
9]. Each cell line displayed a separate gene cluster regard-
less of the drug used (Figure 7B), while no significant clus-
ters were obtained for each specific drug treatment (data
not shown). Interestingly, cell lines displaying quite dif-
ferent responses to cytotoxics when grown as monolayers
(for example SKOV-3 and OVCAR-3) now show very sim-
ilar cluster patterns upon treatment as they cluster adja-
cent to each other (Figure 7B), indicating that differences
in drugs response tend to disappear when these OC cell
lines are grown as multicellular spheroids.
Validation of microarray findings with semi-quantitative 
RT-PCR (sqRT-PCR)
To validate microarray results, we arbitrarily selected 16
differentially expressed genes following different drugs
treatments and quantified their expression by sqRT-PCR
in control and treated spheroids. All sqRT-PCR analyses
were performed in samples previously used for the micro-
array experiments. Table 7 summarizes the gene expres-
sion measurements of all validated genes. We found that
Signal transduction PPARGC1B, AIG1, AKT1, BRE, C16orf45, C20orf23, CABIN1, CAMK1, CHST7, CSNK1A1, CSNK1A1L, DDEF1, 
EDG6, EPS15, FZD1, GNAI1, GNAQ, GNB1, GNB2L1, GNG8, GPR172B, GPS1, GRAP, GRK1, HCG9, IL17R, 
INADL, INPP4B, ITGB1BP2, ITM2C, JAK1, KIAA0174, KRT6E, LMBR1, LPP, MAP2K2, MAP3K4, MAP4K3, 
MAP4K5, MAPBPIP, MRAS, MYH13, NMBR, NRTN, OMP, OR2T5, OR2Z1, PITPNC1, PKIG, PRKCSH, PRR14, 
PSTPIP1, PTD004, PTK7, PTK9L, PTPN11, RAB31, RAC3, RAN, RAP2B, RHO, SMAD3, SPHK1, STC2, STOML2, 
TNFRSF13B, TRABD, TRIM54, USH1C, WNT1, WNT3A, LPHN2
Transport ABCC1, ABCC4, ABCC6, ACTR1B, ANXA6, AP1S3, ATP5G2, ATP6V0E2, CHMP6, CLIC4, COL4A1, CORO1A, 
COX7A2L, CYC1, DLG2, DOT1L, EPN1, ETFDH, FLJ10815, FLJ22659, FTHL17, FTL, GABARAP, HBM, ITSN1, 
KCNJ13, KCNK3, KDELR1, KPNA4, LMAN2, LYRM4, MSCP, NBEA, NDUFA12L, NDUFS2, NDUFS6, NDUFS7, 
NQO2, PTPRG, R30953_1, RAB1A, RAG2, SCNN1D, SEC14L5, SEC24C, SEC5L1, SEC61A1, SEC8L1, SFXN4, 
SLC12A6, SLC25A29, SLC37A1, SLC6A8, SNX15, SNX17, SYNE2, THADA, TUSC3, TXN2, TXNDC4, TXNRD1, 
SLC25A6, FCHSD2
Table 5: Selected differentially expressed gene groups upon topotecan treatment. (Continued)
Functional analysis for a dataset of differentially expressed genes (≥1.5 fold) in OC spheroids following CT drugs treatmentsigure 4
Functional analysis for a dataset of differentially expressed genes (≥1.5 fold) in OC spheroids following CT drugs treatments. A. 
Functional analysis following topotecan treatment, B. Functional analysis following paclitaxel treatment. Top functions that 
meet a p-value cutoff of 0.05 are displayed.
A.    
Up-regulated upon TPT treatment                                    Down-regulated upon TPT treatment
B.    
Up-regulated upon PAC treatment                                    Down-regulated upon PAC treatmentPage 12 of 21
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detected similar patterns for the up- and down-regulated
genes selected for validation.
Discussion
In attempt to identify detailed molecular mechanisms of
drugs actions and early response to CT treatment, we per-
formed gene expression profiling of OC spheroid cultures
treated with cisplatin, topotecan and paclitaxel. To our
knowledge, the present work represents the first effort to
define global changes in gene expression in CT drugs-
treated OC spheroid models by using high-density micro-
arrays. We used six OC cell lines for spheroid formation
that displayed diverse response following treatment with
different drugs in order to identify common mechanisms
of early response to drug action in OC. Indeed, the six
monolayer cell cultures displayed variable chemosensitiv-
ity against cisplatin, while following paclitaxel and topo-
Network analysis of dynamic gene expression in OC spheroids based on the 1.5-fold common gene expression list obtained follo ing topotecan treat entFigure 5
Network analysis of dynamic gene expression in OC spheroids based on the 1.5-fold common gene expression list obtained 
following topotecan treatment. The five top-scoring networks were merged and are displayed graphically as nodes (genes/gene 
products) and edges (the biological relationships between the nodes). Figure legends are as described in Fig. 2.Page 13 of 21
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cell lines with one exception: the TOV-21 line showed sig-
nificantly higher IC50 value upon topotecan treatment
than the remaining cell lines (Table 1). However, these
differences tend to disappear as the same cell lines were
grown as multicellular spheroids. We have checked for the
numbers of apoptotic cells in paraffin embedded sphe-
roid structures by DAPI staining and were not able to find
significant differences in drugs-treated spheroids with
similar morphology (compact spheroids or loose aggre-
gates) that were propagated from cell lines displaying
quite variable chemosensitivities as monolayers (data not
shown). The above observation was also confirmed by
our cluster analysis.
Network analysis of dynamic gene expression in OC spheroids based on the 1.5-fold common gene expression list obtained follo ing paclitaxel treatmentFigure 6
Network analysis of dynamic gene expression in OC spheroids based on the 1.5-fold common gene expression list obtained 
following paclitaxel treatment. The three top-scoring networks were merged and are displayed graphically as nodes (genes/
gene products) and edges (the biological relationships between the nodes). Figure legends are as described in Fig. 2.Page 14 of 21
(page number not for citation purposes)
BMC Genomics 2008, 9:99 http://www.biomedcentral.com/1471-2164/9/99We analyzed both functionally related genes that were
commonly differentially expressed following all drugs
treatments, as well as alterations in gene expression pat-
terns that were specific for each of the three drugs used
(cisplatin, topotecan and paclitaxel). As the main goal of
CT treatment is the induction of apoptosis, we noticed a
comparative number of apoptosis-related genes that were
up- and down-regulated following all treatments (Table
2). Similar expression patterns of apoptosis-related genes
were observed upon cisplatin and topotecan treatments,
while paclitaxel uniquely induced the up-regulation of
several pro-apoptotic genes (BAG5, GULP1 and BAX).
While induction of pro-apoptotic genes is expected upon
treatment with chemotherapeutics, the down-regulation
of genes implicated in apoptosis upon exposure to cispla-
tin and topotecan could be indicative for some compen-
Table 6: Selected differentially expressed gene groups upon paclitaxel treatment.
A. Up-regulated genes
Apoptosis BAG5, GULP1, BAX
Cell cycle SEPT10, C10orf9, TAF1L
Cell adhesion CELSR3, CLDN2, COL24A1, SYMPK, TNXB, CTTN, GJA10
Cytoskeleton CDC42, K-ALPHA-1, TUBA1, TUBA3, TUBA4, TUBA6, TUBB, TUBB2, TUBB3, TUBB4, TUBB6
Metabolism EBPL, OSBP, OSBP2, PAQR6, AMAC1L2, AOC2, ASAH2, CL640, MDH1, NDUFA4, FAM3D
Protein biosynthesis & modification MRPL13, RPL39, RPS29, PTP4A3, DNAJB5, MGAT2, RNF149, RNF44, TRIM21
Response to stress MT2A, C2D1A, IKIP, TFG
Signal transduction BZRP, DUSP9, EFNA3, LPHN1, LRP6, NRAS, SNX24, STARD8, WNT10A
Transport ATP2B3, CNO, GRASP, KCNJ9, PRRG2, RBP4, S100A10, SLC25A17, SLC25A24, TMCO3, TPCN2, TRAM2
B. Down-regulated genes
Cell growth & proliferation HDGF2, PDAP1, MT3, DOT1L, H2BFS, HIST1H1B, SAFB, VCX-C
Cell cycle PARD6G, PLK1, DDIT3, DDIT4, MXD4
Immune response C1QL1, HLA-A, HLA-E, LAT, SLPI, TNFRSF13B
Metabolism HDLBP, PSAP, ALDOA, DHPS, DHRS10, ENO1B, G6PD, HAGHL, IMPDH2, NUDT14, PSMC3, SDHA
Protein biosynthesis & modification EIF4G1, MRPL12, MRPL23, RPL10L, VARS2, FLOT1, BCKDK, CKAP1, GALNT9, KIAA1542
Regulation of transcription ZNF317, ZNF225, ATF5, CEBPE, DBP, ZNF665, ZFP3, ZFP41, ING5, MAF1, MBD3, NFE2L1, POLR2E, ZBTB16, 
ZFP276, ZNF208, ZNF214, ZNF221, ZNF257, ZNF425, ZNF432, ZNF473, ZNF511, ZNF529, ZNF583, 
ZNF585B, ZNF79, ZNF155
Signal transduction DUSP24, ARHGEF10L, GPR172B, GPR20, GRM4, MAPK12, OR2T5, PRKCSH, RAB3D, TMEPAI
Transport CLTB, COX6A2, EPN1, GRPEL1, KCNJ13, SEC14L5, MGC19604, RNP24, SLC12A6, SLC37A1, TIMM44, TLOC1, 
ATP5B, ABCC6
Response to stress MT3, GATA3, HSPA1A
Table 7: Semi-quantitative RT-PCR validation of microarray data.
Treatment Gene Common name Fold expression p-value
Microarray sqRT-PCR
All BRCA1 breast cancer 1 2,12 1,44 0,0257
All CASP7 caspase 7 1,53 1,48 0,0625
All COL25A1 collagen, type XXV, alpha 3,83 1,48 0,0313
All TLR8 toll-like receptor 8 3,6 1,55 0,0049
All COX2 cytochrome c oxidase II 1,57 1,31 0,0562
All SEC8 secretory protein SEC8 -2,02 -1,27 0,0488
cisplatin GMNN Geminin 1,97 1,39 0,0612
cisplatin KCNC1 potassium voltage-gated channel, 1 3,56 1,26 0,0313
cisplatin LY96 Lymphocyte antigen 96 9,96 1,78 0,0303
cisplatin TYMS thymidilate synthase 2,25 1,3 0,0244
topotecan AHR aryl hydrocarbon receptor 1,98 1,43 0,0386
topotecan NR4A1 nuclear receptor subfamily 4, A1 3,17 1,4 0,033
topotecan S100A2 S100 calcium binding protein A2 2,27 1,72 0,0247
topotecan HLA-E major histocompatibility complex, IE -3,02 -1,25 0,0231
paclitaxel TUBA4 tubulin, alpha 2,59 1,35 0,0247
paclitaxel TUBB3 tubulin, beta 3 2,51 1,62 0,0135Page 15 of 21
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[20].
Treating spheroids with chemotherapeutics affected
strongly the regulation of the cell cycle, as a number of
genes implicated in cell cycle control, including genes
involved in cell cycle arrest, were found to be induced
especially following cisplatin and topotecan treatments.
Although cell cycle deregulation events could lead to
apoptosis induction, cell cycle arrest could constitute a
significant event in the survival of the spheroids following
a major stress like CT treatment [21,22]. Moreover, cell
A. Example images of compact and aggregate spheroid structures derived from OC cellsFigure 7
A. Example images of compact and aggregate spheroid structures derived from OC cells. B. Hierarchical clustering of OC 
spheroids following treatment with all used drugs (cisplatin, topotecan and paclitaxel (taxol)), that discriminates between com-
pact spheroids and aggregates. A subset of candidate genes were initially obtained by filtering on signal intensity (2-fold), retain-
ing 527 genes. One-way ANOVA parametric test (Welch t-test, variances not assumed equal, p ≤ 0.03) further selected 85 
genes. Clustering analysis based on the 85 gene list was performed using the standard Condition Tree algorithm provided in 
GeneSpring. The mean appears grey, whereas red signifies up-regulation, and green signifies down-regulation (see legend bar). 
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mechanisms [23], as a number of DNA repair genes
(BRCA1, BRCA2, DDB2, FANCA) were found to be up-reg-
ulated in OC spheroids following all treatments. Indeed,
BRCA1 and FANCA (a member of the Fanconi Anemia
family of proteins) are involved in detecting DNA dam-
age, causing cell cycle arrest and allowing DNA repair,
which contributes to chemoresistance [24], while disrup-
tion of the BRCA1 pathway may promote sensitivity to
platinum-based therapies [25,26]. A marked up-regula-
tion of genes encoding for DNA replication and repair
proteins was particularly evident following exposure to
cisplatin (Table 4A). This was not surprising since cispla-
tin action in OC cells implies the formation of DNA
adducts that enable physiological processes such as repli-
cation and transcription, leading to oxidative stress and
enhanced DNA repair [27,28]. Topotecan treatment led to
comparative up- and down-regulation of DNA replication
and repair genes (Table 5). Thus, our data obtained with
the OC spheroid model are confirmative to previously
proposed mechanisms of cisplatin and topotecan action
in OC cells associated with enhanced DNA replication
and repair [29,30].
Likewise, different genes functionally involved in cellular
assembly and organization (including cell adhesion and
cytoskeleton organization) were comparatively induced
or suppressed following exposure to the three drugs used.
Indeed, a number of cell adhesion-related genes, includ-
ing some integrins, cadherins and claudins, were down
regulated upon all drugs treatments (Table 2B). As dem-
onstrated, a destabilization of the cellular adhesion in
spheroids following treatment was causal for apoptosis
induction [31]. Moreover, it is recognized that the stabil-
ity of the cellular adhesion in spheroid cultures is closely
related to the stability of the cell cytoskeleton [32]. Con-
sequently, various genes functionally implicated in
cytoskeleton organization were commonly down-regu-
lated after all treatments (Table 2B). However, a common
overexpression of cell adhesion and cytoskeleton-related
genes was also observed in all treated OC spheroids, as
well as upon exposure to cisplatin or topotecan, which
probably represents an adaptive answer to CT treatment
(Tables 2A, 4A and 5A).
Paclitaxel treatment resulted exclusively in the induction
of cell adhesion- and cytoskeleton-related genes, (includ-
ing numerous tubulin genes) in OC spheroids (Table 6A).
Although class III beta-tubulin overexpression was previ-
ously associated with paclitaxel resistance in OC [33], to
our knowledge, such a major overexpression of various
tubulin genes in cancer cells upon paclitaxel exposure has
been not demonstrated previously. Since the principal
mechanism of paclitaxel action implies a deregulation of
the microtubules dynamics by promoting and stabilizing
microtubule formation and inhibiting microtubule depo-
lymerization [34], the increased expression of different
tubulin isotypes could partially compensate paclitaxel
action by altering the dynamic equilibrium between solu-
ble and polymerized tubulin that exists in the absence of
drug.
Our data support previous reports that multicellular/
adhesion-mediated survival mechanism could render
both normal and cancer epithelial cells less vulnerable to
undergoing drug-induced apoptosis [35,36]. Indeed, mul-
ticellular resistance can only be demonstrated in three-
dimensional cultures and fails to be shown in monolayers
or cell suspensions. This is explained by the fact that cell-
to-cell and cell-to-stroma adhesion limits drug penetra-
tion, and by the variable susceptibility to cytotoxicity
determined by oxygen and tissue proliferation gradients
[17]. Thus, an increase of cellular adhesion in spheroids
was previously associated with a resistance to antineopla-
sic agents [17,37]. Our comparison of the gene expression
patterns in OC spheroids with different morphology,
including compact spheroids or more loose structures
(cellular aggregates), demonstrated certain differences in
response to treatment, as found by gene cluster analysis
(Figure 7B). More specifically, gene clustering was indica-
tive for overexpression of several cell adhesion genes
(CSPG3, ITGAV, MUC1) in the compact spheroid struc-
tures in comparison to the aggregates, which could be
determinative for the observed variations in spheroid's
morphology and response to treatment. Taken together,
these results suggest that some aspects of cisplatin, topo-
tecan, or paclitaxel early resistance in ovarian carcinoma
may be multicellular/adhesion-dependent or associated
[38-40].
As expected, upon all drugs treatments we monitored
down-regulation of numerous genes that are functionally
associated with metabolism, signal transduction, gene
expression, protein biosynthesis and modification,
immune response/inflammation, and molecular trans-
port. As a matter of fact, suppressed transcription and
lower metabolism rates have been previously linked with
chemotherapeutics action [41-43]. We want to specifically
note that a significant number of genes involved in lipid
metabolism were found to be suppressed in CT drugs-
treated OC spheroids (Table 2B). Indeed, OC patients
exhibit altered lipid metabolism and the degree of these
alterations have been previously linked with response to
therapy, as these metabolic alterations may influence dis-
ease outcome [44,45]. Our previous work suggested that
lower lipid metabolism rates might improve treatment
response in OC patients [13]. Thus, the observed lower
expression of genes involved in lipid metabolism might
be associated with an immediate mechanism of drugs
action in OC spheroids.Page 17 of 21
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show expression changes is important, there is an increas-
ing need to move beyond this level of analysis. Instead of
simply enumerating a list of genes, we wanted to know
how they interact as parts of complexes, pathways and
biological networks. For this purpose, the microarray data
were imported into the IPA software to identify relevant
biological pathways and networks. Pathway and network
analyses were highly confirmative of the gene expression
data obtained. Indeed, specific functional pathways dis-
played similar expression patterns in cisplatin- or topote-
can-treated OC spheroids which were rather comparable
to those observed upon all drugs treatments (Figures
1A,1B and 2A). Network analysis was indicative for
important roles of some genes and related networks
(BRCA1, CDKN1 (p21) and CASP3) in the mode of action
of these drugs (Figures 3, 4, 5). This similarity was not
unexpected because both cisplatin and topotecan action
triggers the formation of DNA lesions which interfere with
and inhibit DNA replication.
Network analysis was also suggestive for the important
role of TGFβ1 and related network in cisplatin action (Fig-
ure 4). The role of TGFβ1 in the cellular response to cispl-
atin is not well defined. However, TGFβ1 is known to be
involved in tumor suppression [46,47] and its down-reg-
ulation following cisplatin treatment could represent a
compensatory mechanism to this drug action.
Topotecan, a topoisomerase-I inhibitor, is most fre-
quently used as a second-line CT treatment of recurrent
OC [43]. Analysis of the various biologic pathways and
networks implicated in the cellular response to topotecan
showed similarities with cisplatin action (including over-
expression of CASP3, CDKN1, CDC2; see Figure 5). How-
ever, various other genes and related pathways, associated
with cell growth and survival (AKT1, WNT1, IGFR1,
CCND1) were specifically down-regulated after topotecan
treatment (Figure 5), which is probably relevant to the
specific mechanisms of cytotoxic action of this drug in OC
cells.
Pathway and network analyses of paclitaxel action in OC
spheroids demonstrated comparative up- and down regu-
lation of genes functionally associated with metabolism,
protein biosynthesis and modification, signal transduc-
tion and transport, and were again quite confirmative of
the gene expression data obtained with this drug (see Fig-
ures 2A and 6).
Conclusion
We used the OC spheroid model to define global changes
in gene expression that are linked to the molecular mech-
anisms of CT drugs action and early response to treat-
ment. Exposure of OC spheroids to significantly high
concentrations of CT drugs such as cisplatin, topotecan
and paclitaxel (see Table 1) resulted in differential expres-
sion of genes, functionally associated with to cell growth
and proliferation, cellular assembly and organization, cell
death, cell cycle control and cell signaling. Genes and cor-
responding pathways implicated in cell cycle arrest, DNA
replication and repair were predominantly overexpressed,
while genes associated with transcription control, metab-
olism, transport, immune and inflammatory response
were mostly down-regulated. Cisplatin and topotecan
treatments triggered similar alterations in gene and path-
way expression patterns, while paclitaxel action was
mainly associated with induction of genes and pathways
linked to cellular assembly and organization, cell death
and protein synthesis. Most alterations in gene expression
were directly related to mechanisms of cytotoxic actions of
the CT drugs in OC spheroids. However, the induction of
genes linked to mechanisms of DNA replication and
repair in cisplatin- and topotecan-treated OC spheroids
could be associated with immediate compensatory
response to treatment. Similarly, overexpression of differ-
ent tubulin genes upon exposure to paclitaxel could rep-
resent an early adaptive effect to this drug action. Finally,
changes in relevant drug-resistance associated gene
expression brought about by multicellular growth condi-
tions that are known to alter gene expression (including
cell adhesion and cytoskeleton organization), could sub-
stantially contribute in reducing the initial effectiveness of
CT drugs in OC.
Results described in this study underscore the potential of
the microarray technology for unraveling the complex
mechanisms of CT drugs actions in OC spheroids and ini-
tial protective responses to cytotoxic treatment. Although
not directly clinically relevant, our data could be indica-
tive for some early events that might be implicated in the
onset of acquired OC chemoresistance.
Methods
Cell cultures and spheroid formation
The OC cell lines used were either purchased from ATCC
(OVCAR3, SKOV3), or were previously isolated and char-
acterized (TOV-112, TOV-21, OV-90), as described [48].
The TOV-155 cell line was recently established in our lab
as spontaneously immortalized cyst adenoma cell line
and the detailed characterization of this cell line will be
reported elsewhere. More detailed information of the cell
lines used is presented on Table 1. Multicellular spheroids
were prepared by a liquid overlay method [49]. Briefly,
the wells were coated with 0.5 ml of 0.6% agarose con-
taining serum-free medium. Tumor cells grown in the
complete medium were then transferred to the top of
solidified agarose. After culturing for 3 days, multicellular
spheroids were formed on the agarose surface. The culture
medium was changed partially every 24 h.Page 18 of 21
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Gene expression analysis was carried out as previously
described [13,14]. Briefly, total RNA was isolated from CT
drug-treated or control OC spheroid cultures using the
Trizol reagent (Invitrogen, Burlington ON, Canada). The
quality of all RNA samples was examined by capillary
electrophoresis using the Agilent 2100 Bioanalyzer (Agi-
lent, Palo Alto, CA). Fluorescently labeled cDNAs were
generated from 20 μg of total RNA in each reaction using
the Agilent Fluorescent Direct Label Kit and 1.0 mM Cya-
nine 3- or 5-labeled dCTP (PerkinElmer, Boston, MA),
and following user's manual. Cyanine-labeled cDNA from
CT drug-treated spheroids was mixed with the same
amount of reverse-color cyanine labeled cDNA from the
corresponding control (vehicle-treated) spheroids and
were applied to the Human 1A (v2) Oligonucleotide
Microarray (Agilent), containing 20,174 genes. Upon
hybridization and washing, the arrays were scanned using
a dual-laser DNA microarray scanner (Agilent). The data
were then extracted from images by the Feature Extraction
software 6.1 (Agilent). The GeneSpring software (Agilent)
was used to generate lists of selected genes and for differ-
ent statistical and visualization methods. An Intensity-
Dependent Normalization (known as Lowess normaliza-
tion) was applied to correct for artifacts caused by nonlin-
ear rates of dye incorporation as well as inconsistencies of
the relative fluorescence intensity between some red and
green dyes. Consecutive lists of differentially expressed
genes were generated considering a 1.5-fold expression as
gene selection criteria for the different experimental con-
ditions are indicated in the Results section. Comparisons
of gene expression in compact spheroids and loose aggre-
gates were performed by Cluster Analysis the using Con-
dition Tree algorithm. The genes in the gene lists were
classified according to their function using the Gene
Ontology (GO SLIMS) classification system. Network
analysis of the microarray data was completed using the
Ingenuity Pathway Analysis software [50].
Semi-quantitative duplex RT-PCR (sqRT-PCR)
Validation of microarray data was performed for selected
differentially expressed genes by sqRT-PCR as previously
described [13,14]. The peptidylprolyl isomerase A-like
(PPIAL) gene was uniformly expressed in all OC spheroid
cultures analyzed (control and treated) and was used as
internal standard. Primers were designed for these loci
with the sequences freely available from the Entrez Nucle-
otide database and the Primer3 algorithm for primer
design [51]. One-fifth of each PCR reaction was run on a
1.5–2% agarose gel in 1×TBE buffer (45 mM Tris/borate/
1 mM EDTA); the gel was documented using the AlphaIm-
ager 2200 gel documentation system (Alpha Innotech,
San Leandro, CA) and analyzed using the publicly availa-
ble NIH ImageJ 1.33u program [52]. Each expression
value was calculated as a relative ratio between the signal
of the specific PCR fragment and that of the internal PPIAL
standard. The data obtained were statistically analyzed by
the paired t-test using the GraphPad InStat Software ver-
sion 3.06 (San Diego CA).
MTT assay
The MTT cell proliferation assay (Sigma, St-Louis, MS,
USA) was used to measure the cell growth inhibition
effects of the CT drugs (cisplatin, topotecan and paclit-
axel) in the six OC cell lines, grown as monolayers. Cell
suspensions (at 2 × 104 cells/ml) were transferred to 96-
well plates in multiple replicates (×5) and incubated for 3
days with different drug's concentrations (ranging
between 1 nM and 100 μM). Then, 38 μl of 3-[4,5-dimeth-
ylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT,
5 mg/ml) was added to each well 4 h before the end of the
incubation. After centrifugation and removing the super-
natant, 200 μL of dimethyl sulphoxide (DMSO) were
added to resolve the crystals and the optical density was
measured by microplate reader at 595 nm.
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